You are about to be redirected to a site intended for people with primary HLH or their caregivers.
You are being redirected to a third party website.
Sobi takes no responsibility for the content of this website.
Gamifant is the only treatment specifically designed to target and neutralize interferon gamma (IFNγ), a key upstream mediator of the proinflammatory cytokine storm associated with primary hemophagocytic lymphohistiocytosis (HLH).1-4
Gamifant is a monoclonal antibody that binds to soluble and receptor-bound forms of IFNγ. Binding to IFNγ neutralizes its activity, blocking its intracellular signaling to inhibit macrophage activation and the downstream release of proinflammatory cytokines.1-7
Click through to see how Gamifant blocks IFNγ and subdues the cytokine storm.
In a clinical trial, sustained and consistent reductions in the plasma concentrations of CXCL9 showed that IFNγ was effectively neutralized by Gamifant.1,5See the data
CXCL9 is one of three chemokines in the CXC subfamily predominantly induced by IFNγ. CXCL9 helps regulate immune responses, hematopoietic development, and cell-to-cell communication by acting as a mediator and modulator.9-13
In primary HLH, CXCL9 is produced by IFNγ-activated macrophages. CXCL9 is also a chemoattractant for activated T cells, especially the Th1 cells that produce IFNγ. Thus, higher levels of CXCL9 can indicate IFNγ activity.12
Primary hemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory condition that mostly affects children, but can also occur in adults and teenagers.4,14-16
Gamifant reduces the inflammatory symptoms of primary HLH by neutralizing IFNγ.1
Gamifant is given as an intravenous infusion twice a week until hematopoietic stem cell transplantation (HSCT) is performed.1
Download the Start Form now or contact Gamifant Patient Services at 833.597.6530.